Thyroid hormones inhibit TGF-β signaling and attenuate fibrotic responses

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 24, 2016, Pages E3451-E3460

  Alonso Merino, Elvira ^a   Orozco, Rosa Martín ^a   Ruíz Llorente, Lidia ^a   Martínez Iglesias, Olaia A ^a   Velasco Martín, Juan Pedro ^a   Montero Pedrazuela, Ana ^a   Fanjul Rodríguez, Luisa ^a   Contreras Jurado, Constanza ^a   Regadera, Javier ^a   Aranda, Ana ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Fibrosis; SMADs; TGF ; Thyroid hormone receptors

Indexed keywords

CELL NUCLEUS RECEPTOR; LIOTHYRONINE; PROTEIN P15; SMAD PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; BLEOMYCIN; SMAD3 PROTEIN, MOUSE; SMAD4 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARBON TETRACHLORIDE-INDUCED LIVER FIBROSIS; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; COS 1 CELL LINE; DNA BINDING; FEMALE; FIBROGENESIS; GENE EXPRESSION; HELA CELL LINE; HEPG2 CELL LINE; HISTONE ACETYLATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; TRANSACTIVATION; TRANSCRIPTION INITIATION; ANIMAL; CHEMICALLY INDUCED; GENETICS; INTOXICATION; KNOCKOUT MOUSE; LIVER CIRRHOSIS; METABOLISM; PATHOLOGY;

ANIMALS; BLEOMYCIN; CARBON TETRACHLORIDE POISONING; LIVER CIRRHOSIS; MICE; MICE, KNOCKOUT; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRIIODOTHYRONINE;

EID: 84974733602     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1506113113     Document Type: Article

References (57)

1. Massagué J (2012) TGFβ signalling in context. Nat Rev Mol Cell Biol 13(10):616-630.
2. Bataller R, Brenner DA (2005) Liver fibrosis. J Clin Invest 115(2):209-218.
3. Hernandez-Gea V, Friedman SL (2011) Pathogenesis of liver fibrosis. Annu Rev Pathol 6:425-456.
4. Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA (2014) Liver fibrosis and repair: Immune regulation of wound healing in a solid organ. Nat Rev Immunol 14(3):181-194.
5. Clouthier DE, Comerford SA, Hammer RE (1997) Hepatic fibrosis, glomerulosclerosis, and a lipodystrophy-like syndrome in PEPCK-TGF-beta1 transgenic mice. J Clin Invest 100(11):2697-2713.
6. Dooley S, ten Dijke P (2012) TGF-β in progression of liver disease. Cell Tissue Res 347(1):245-256.
7. Seki E, et al. (2007) TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 13(11):1324-1332.
8. Weng HL, et al. (2009) The etiology of liver damage imparts cytokines transforming growth factor beta1 or interleukin-13 as driving forces in fibrogenesis. Hepatology 50(1):230-243.
9. Yamamoto T, Takagawa S, Katayama I, Nishioka K (1999) Anti-sclerotic effect of transforming growth factor-beta antibody in a mouse model of bleomycin-induced scleroderma. Clin Immunol 92(1):6-13.
10. Inagaki Y, Okazaki I (2007) Emerging insights into Transforming growth factor beta Smad signal in hepatic fibrogenesis. Gut 56(2):284-292.
11. Feng XH, Derynck R (2005) Specificity and versatility in tgf-beta signaling through Smads. Annu Rev Cell Dev Biol 21:659-693.
12. Heldin CH, Moustakas A (2012) Role of Smads in TGFβ signaling. Cell Tissue Res 347(1): 21-36.
13. Mullen AC, et al. (2011) Master transcription factors determine cell-type-specific responses to TGF-β signaling. Cell 147(3):565-576.
14. Ross S, et al. (2006) Smads orchestrate specific histone modifications and chromatin remodeling to activate transcription. EMBO J 25(19):4490-4502.
15. Kavsak P, et al. (2000) Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell 6(6):1365-1375.
16. Breitkopf K, Godoy P, Ciuclan L, Singer MV, Dooley S (2006) TGF-beta/Smad signaling in the injured liver. Z Gastroenterol 44(1):57-66.
17. Lakos G, et al. (2004) Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma. Am J Pathol 165(1):203-217.
18. Schnabl B, et al. (2001) The role of Smad3 in mediating mouse hepatic stellate cell activation. Hepatology 34(1):89-100.
19. Takagawa S, et al. (2003) Sustained activation of fibroblast transforming growth factor-beta/Smad signaling in a murine model of scleroderma. J Invest Dermatol 121(1):41-50.
20. Yoshida K, et al. (2005) Transforming growth factor-beta and platelet-derived growth factor signal via c-Jun N-terminal kinase-dependent Smad2/3 phosphorylation in rat hepatic stellate cells after acute liver injury. Am J Pathol 166(4):1029-1039.
21. Aranda A, Alonso-Merino E, Zambrano A (2013) Receptors of thyroid hormones. Pediatr Endocrinol Rev 11(1):2-13.
22. Brent GA (2012) Mechanisms of thyroid hormone action. J Clin Invest 122(9): 3035-3043.
23. Pascual A, Aranda A (2013) Thyroid hormone receptors, cell growth and differentiation. Biochim Biophys Acta 1830(7):3908-3916.
24. Mullur R, Liu YY, Brent GA (2014) Thyroid hormone regulation of metabolism. Physiol Rev 94(2):355-382.
25. Sinha RA, Singh BK, Yen PM (2014) Thyroid hormone regulation of hepatic lipid and carbohydrate metabolism. Trends Endocrinol Metab 25(10):538-545.
26. López-Fontal R, et al. (2010) Mice lacking thyroid hormone receptor Beta show enhanced apoptosis and delayed liver commitment for proliferation after partial hepatectomy. PLoS One 5(1):e8710.
27. Zambrano A, et al. (2014) The thyroid hormone receptor β induces DNA damage and premature senescence. J Cell Biol 204(1):129-146.
28. Perra A, Kowalik MA, Pibiri M, Ledda-Columbano GM, Columbano A (2009) Thyroid hormone receptor ligands induce regression of rat preneoplastic liver lesions causing their reversion to a differentiated phenotype. Hepatology 49(4):1287-1296.
29. Chung GE, et al. (2012) Non-alcoholic fatty liver disease across the spectrum of hypothyroidism. J Hepatol 57(1):150-156.
30. Perra A, et al. (2008) Thyroid hormone (T3) and TRbeta agonist GC-1 inhibit/reverse nonalcoholic fatty liver in rats. FASEB J 22(8):2981-2989.
31. Pihlajamäki J, et al. (2009) Thyroid hormone-related regulation of gene expression in human fatty liver. J Clin Endocrinol Metab 94(9):3521-3529.
32. Silveira MG, Mendes FD, Diehl NN, Enders FT, Lindor KD (2009) Thyroid dysfunction in primary biliary cirrhosis, primary sclerosing cholangitis and non-alcoholic fatty liver disease. Liver Int 2009;29(7):1094-1100.
33. Martínez-Iglesias O, et al. (2009) Thyroid hormone receptor beta1 acts as a potent suppressor of tumor invasiveness and metastasis. Cancer Res 69(2):501-509.
34. Wrana JL, et al. (1992) TGF beta signals through a heteromeric protein kinase receptor complex. Cell 71(6):1003-1014.
35. García-Silva S, Martínez-Iglesias O, Ruiz-Llorente L, Aranda A (2011) Thyroid hormone receptor β1 domains responsible for the antagonism with the ras oncogene: Role of corepressors. Oncogene 30(7):854-864.
36. Rastinejad F, Perlmann T, Evans RM, Sigler PB (1995) Structural determinants of nuclear receptor assembly on DNA direct repeats. Nature 375(6528):203-211.
37. Lin X, et al. (2006) PPM1A functions as a Smad phosphatase to terminate TGFbeta signaling. Cell 125(5):915-928.
38. Zhu XG, Hanover JA, Hager GL, Cheng SY (1998) Hormone-induced translocation of thyroid hormone receptors in living cells visualized using a receptor green fluorescent protein chimera. J Biol Chem 273(42):27058-27063.
39. Feng XH, Lin X, Derynck R (2000) Smad2, Smad3 and Smad4 cooperate with Sp1 to induce p15(Ink4B) transcription in response to TGF-beta. EMBO J 19(19):5178-5193.
40. von Gersdorff G, et al. (2000) Smad3 and Smad4 mediate transcriptional activation of the human Smad7 promoter by transforming growth factor beta. J Biol Chem 275(15): 11320-11326.
41. Liang YY, Brunicardi FC, Lin X (2009) Smad3 mediates immediate early induction of Id1 by TGF-beta. Cell Res 19(1):140-148.
42. Massagué J, Seoane J, Wotton D (2005) Smad transcription factors. Genes Dev 19(23): 2783-2810.
43. Obregon MJ, Pascual A, de Escobar GM, Escobar del Rey F (1979) Pituitary and plasma thyrotropin, thyroxine, and triiodothyronine after hyperthyroidism. Endocrinology 104(5):1467-1473.
44. Yoshida K, Matsuzaki K (2012) Differential Regulation of TGF-β/Smad Signaling in Hepatic Stellate Cells between Acute and Chronic Liver Injuries. Front Physiol 3:53.
45. Pritchard MT, Cohen JI, Roychowdhury S, Pratt BT, Nagy LE (2010) Early growth response- 1 attenuates liver injury and promotes hepatoprotection after carbon tetrachloride exposure in mice. J Hepatol 53(4):655-662.
46. Yamamoto T, et al. (1999) Animal model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 112(4):456-462.
47. Shibusawa N, et al. (2003) Thyroid hormone action in the absence of thyroid hormone receptor DNA-binding in vivo. J Clin Invest 112(4):588-597.
48. Nicolás FJ, De Bosscher K, Schmierer B, Hill CS (2004) Analysis of Smad nucleocytoplasmic shuttling in living cells. J Cell Sci 117(Pt 18):4113-4125.
49. Rosenbloom J, Castro SV, Jimenez SA (2010) Narrative review: Fibrotic diseases: Cellular and molecular mechanisms and novel therapies. Ann Intern Med 152(3):159-166.
50. Contreras-Jurado C, et al. (2011) The thyroid hormone receptors as modulators of skin proliferation and inflammation. J Biol Chem 286(27):24079-24088.
51. Bagnato G, et al. (2013) Propylthiouracil prevents cutaneous and pulmonary fibrosis in the reactive oxygen species murine model of systemic sclerosis. Arthritis Res Ther 15(5):R120.
52. Bruck R, et al. (1998) Hypothyroidism minimizes liver damage and improves survival in rats with thioacetamide induced fulminant hepatic failure. Hepatology 27(4): 1013-1020.
53. Ghose Roy S, Mishra S, Ghosh G, Bandyopadhyay A (2007) Thyroid hormone induces myocardial matrix degradation by activating matrix metalloproteinase-1. Matrix Biol 2007;26(4):269-279.
54. Zhang Y, et al. (2013) Both hypothyroidism and hyperthyroidism increase atrial fibrillation inducibility in rats. Circ Arrhythm Electrophysiol 6(5):952-959.
55. Lin Y, Sun Z (2011) Thyroid hormone ameliorates diabetic nephropathy in a mouse model of type II diabetes. J Endocrinol 209(2):185-191.
56. Ding N, et al. (2013) A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell 153(3):601-613.
57. Ito I, et al. (2013) A nonclassical vitamin D receptor pathway suppresses renal fibrosis. J Clin Invest 123(11):4579-4594.